This website is a presentation of myeloma and the NMSG. The content of the website is for information exclusively. The information given on this site is not meant to and cannot replace professional counseling or treatment by a doctor. The information is not to be used for diagnosing or determining a treatment.

NMSG does not guarantee for the correctness of information of this website or websites to which referrals are made. NMSG cannot be held responsible neither directly nor indirectly for any damage or loss caused by your or a third party´s use or misuse of the website. All rights to the website and to material on the website belong to NMSG. This also applies to all written entries sent to the website. Entries, which are sent to the website, become the property of NMSG and may without limitation be used by NMSG and are treated without confidence. Any dispute that may arise regarding this website or as a consequence of using this website is to be settled according to Danish Law. NMSG is not responsible for direct, random, consequently indirect or criminal damages which may occur due to the access to or the use of the content on this website, including computer viruses, regardless of the accurateness or completeness.

Clinical Guidelines

The NMSG do not write common Nordic Guidelines for the treatment of multiple myeloma, but NMSG members participate in the national committees writing the national guidelines in each country. We have one common guideline on the use of allogenic transplantation in multiple myeloma. Here you find this and all the national guidelines. 

NMSG
NMSG Recommendations for allogenic hematopoietic stem cell transplantation in multiple myeloma (2017) 

 

Denmark
The Danish Myeloma Study Group (DMSG) provides up to date evidence based guidelines for both clinical and laboratory hematologists on the diagnosis and treatment of hematological disease.
https://myeloma.hematology.dk/index.php/vejledninger-dmsg 

 

Sweden
The Swedish Myeloma Group provides national guidelines for the diagnosis and treatment of myeloma.

http://www.sfhem.se/riktlinjer 

 

Norway
The Norwegian Directorate of Health has published an action plan for myeloma. This is a part of a publication dealing with all kinds of blood diseases (in Norwegian):
https://www.helsedirektoratet.no/tema/kreft/maligne-blodsykdommer

Finland
The Finnish Hematology Association (SHY) provides national guidelines for diagnosis and treatment of myeloma. https://www.hematology.fi/fi/hoito-ohjeet/veritaudit/plasmasolutaudit/myelooma/hoito/kansalliset-hoitosuositukset-fmg

There are currently no published national guidelines for multiple myeloma in Iceland, Lithuania and Estonia. If you’re a doctor in these countries and have questions regarding the treatment of NMSG please contact nearest university hospital for current local guidelines.